Birtamimab Plus Standard-Of-Care in Light Chain Amyloidosis: The Phase 3 Randomized, Placebo-Controlled VITAL Trial

SPONSORED CONTENT: Morie Gertz, MD, reviews data on the use of birtamimab plus standard-of-care anti-plasma cell chemotherapy in patients with light-chain amyloidosis, which was investigated in the phase 3 randomized, placebo-controlled VITAL trial.

Related Content:

Rapid ReadoutsSponsored
Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)